Pill Identifier App

Potassium Acetate

Dosage Form: injection, solution

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Potassium Acetate INJECTION, USP, 2 mEq/mL, 4 mOsmol/mL

Rx Only

100 mL PHARMACY BULK PACKAGE
NOT FOR DIRECT INFUSION

Potassium Acetate Description

Potassium Acetate Injection, USP, 2 mEq/mL, is a sterile, nonpyrogenic solution of Potassium Acetate (C2H3KO2) in Water for Injection. It must be diluted prior to administration.

Slideshow: Doctor Avoidance: 5 Reasons Why It's Not a Good Idea

Each mL contains Potassium Acetate (Anhydrous) 196 mg (equivalent to 2 mEq/mL), Water for Injection q.s. pH may be adjusted with Acetic Acid. Contains no bacteriostatic agent or other preservatives.

Potassium Acetate - Clinical Pharmacology

Potassium is found in low concentration in plasma and extracellular fluids. It is the chief cation of body cells, and is concerned with the maintenance of the body fluid composition and electrolyte balance. The major amount of potassium is excreted in the urine. Therefore, the kidney normally determines potassium balance.

The acetate ion is completely metabolized in the body, providing a source of hydrogen ion acceptors.

Indications and Usage for Potassium Acetate

Potassium Acetate Injection, USP, is indicated in the treatment of potassium deficiency states when oral replacement therapy is not feasible.

The solution is intended as an alternative to Potassium Chloride to provide Potassium (K+) for addition to large volume infusion fluids for intravenous use.

Contraindications

Potassium Acetate Injection, USP, administration is contraindicated in diseases where high potassium levels may be encountered.

Warnings

Potassium Acetate Injection, USP, must be diluted before use. To avoid potassium intoxication, infuse potassium containing solutions slowly. Potassium replacement therapy should be monitored whenever possible by continuous or serial electrocardiography.

Solutions containing potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.

In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention.

Solutions containing acetate ion should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Precautions

Potassium replacement therapy should be guided primarily by serial electrocardiograms. Plasma potassium levels are not necessarily indicative of tissue potassium levels.

High plasma concentrations of potassium may cause death through cardiac depression, arrhythmias or arrest. Potassium Acetate Injection, USP, should be used with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease, metabolic acidosis, Addison’s disease, acute dehydration, prolonged or severe diarrhea, familial periodic paralysis, hypoadrenalism, hyperkalemia, hyponatremia and myotonia congenita.

Pregnancy

Teratogenic Effects

Pregnancy Category C: Safety for use in pregnancy has not been established. Use of Potassium Acetate in women of childbearing potential requires that anticipated benefits be weighed against possible hazards.

Adverse Reactions

Nausea, vomiting, abdominal pain and diarrhea have been reported. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS complex with development of a biphasic curve, and cardiac arrest. (SeeWARNINGSandPRECAUTIONS.)

Overdosage

In the event of overdosage, discontinue the infusion immediately, and institute intensive corrective therapy to reduce the serum potassium levels and restore acid-base balance if necessary. (SeeWARNINGS,PRECAUTIONSandADVERSE REACTIONS.)

Potassium Acetate Dosage and Administration

Potassium Acetate Injection, USP (2 mEq/mL) must be diluted before administration.

The dose and rate of administration are dependent upon the individual condition of each patient. ECG and serum potassium should be monitored as a guide to dosage. Withdraw the calculated volume aseptically and transfer to appropriate intravenous fluids to provide the desired number of milliequivalents of potassium (K+) with an equal number of milliequivalents of acetate (CH3COO−).

Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit. Discard vial within 4 hours of initial entry.

DIRECTIONS FOR DISPENSING FROM 100 mL PHARMACY BULK PACKAGE - NOT FOR DIRECT INFUSION

The 100 mL Pharmacy Bulk Package is for use in a Pharmacy Admixture Service only. The 100 mL Pharmacy Bulk Package should be suspended (inverted) by its IV hang label in a laminar flow hood or biological safety cabinet. Prior to entering a Pharmacy Bulk Package remove the flip-off seal and cleanse the rubber closure with a suitable antiseptic agent. Entry into the Pharmacy Bulk Package must be made with a sterile transfer set or other sterile dispensing device and the contents dispensed in aliquots using aseptic technique. Use of a syringe needle is not recommended as it may cause leakage. ANY UNUSED PORTION MUST BE DISCARDED WITHIN 4 HOURS AFTER INITIAL ENTRY. The date and the time the Pharmacy Bulk Package was initially opened should be recorded in the space provided on the Pharmacy Bulk Package label.

How is Potassium Acetate Supplied

Potassium Acetate Injection, USP 2 mEq/mL

NDC 0517-2053-25 20 mL Single Dose Vial Packaged in boxes of 25
NDC 0517-2450-25 50 mL Single Dose Vial Packaged in boxes of 25
NDC 0517-2400-25 100 mL Pharmacy Bulk Package Packaged in boxes of 25

Store at 20o-25oC (68o-77oF);excursions permitted to 15o-30oC (59o-86oF) (See USP Controlled Room Temperature).

AMERICAN
REGENT, INC
SHIRLEY, NY 11967

IN2053

Rev. 11/05

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPLE DISPLAY PANEL – 20 mL Container

NDC 0517-2053-25

Potassium Acetate INJECTION, USP

40 mEq/20 mL

(2 mEq/mL)

20 mL SINGLE DOSE VIAL

FOR IV USE AFTER DILUTION

Rx Only

AMERICAN REGENT, INC.

SHIRLEY, NY 11967

Potassium Acetate 
Potassium Acetate injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0517-2053
Route of Administration INTRAVENOUS DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Potassium Acetate (POTASSIUM CATION) Potassium Acetate 196 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
ACETIC ACID  
WATER  
Packaging
# Item Code Package Description
1 NDC:0517-2053-25 25 VIAL, SINGLE-DOSE (VIAL) in 1 TRAY
1 20 mL in 1 VIAL, SINGLE-DOSE
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 09/30/1990
Labeler - American Regent, Inc. (622781813)
Revised: 07/2012
 
American Regent, Inc.
Hide
(web4)